Le Lézard
Classified in: Health, Science and technology

South Texas Dermatopathology, PLLC Notifies Patients of Data Security Incident


SAN ANTONIO, July 19, 2019 /PRNewswire/ -- South Texas Dermatopathology, PLLC has been informed by Retrieval Masters Creditors Bureau d/b/a American Medical Collection Agency ("AMCA") of a data security incident involving the AMCA payment website. AMCA is an independent collection agency that South Texas Dermatopathology and many other entities used for debt collection.  The incident is limited to AMCA's systems.  The security of South Texas Dermatopathology's systems was not affected by this incident.

According to AMCA, on March 21, 2019, AMCA became aware of facts indicating there had been a data security incident. After conducting an investigation, in May of 2019, AMCA notified South Texas Dermatopathology about the incident and informed South Texas Dermatopathology that an AMCA database containing information for some South Texas Dermatopathology patients had been affected.  However, at the time of AMCA's initial notification, AMCA did not provide South Texas Dermatopathology with enough information for South Texas Dermatopathology to identify potentially affected patients or confirm the nature of patient information potentially involved in the incident, and South Texas Dermatopathology's investigation is on-going. Based on the information provided by AMCA, the following information belonging to South Texas Dermatopathology patients may have been affected by the incident: patient names, addresses, phone numbers, dates of birth, dates of service, balance information, credit card or banking information and treatment provider information.  AMCA has advised South Texas Dermatopathology that its patient's social security numbers were not involved in the incident.  South Texas Dermatopathology does not provide AMCA healthcare records such as laboratory results and clinical history.

In response to the breach, AMCA sent notification letters to approximately 1,200 South Texas Dermatopathology patients informing them that their names, addresses, phone numbers, dates of birth, dates of service, balance information, credit card or banking information and treatment provider information may have been impacted. In addition, based on the investigation and the information provided by AMCA, South Texas Dermatopathology estimates that approximately another 14,900 patients may have had their names, addresses, phone numbers, dates of birth, dates of service, balance information and treatment provider information impacted by this incident.  For these patients, credit card and banking information is not affected. The impact of this incident is limited to laboratory services provided to patients in the United States whose accounts were referred for debt collection.

Individuals with questions about this incident or questions about precautionary steps they can take may call 833-300-6928 for additional information.

South Texas Dermatopathology takes the security of its patients' information very seriously, including the security of data handled by vendors.  As a result of the investigation, South Texas Dermatopathology is no longer using AMCA for collection efforts.

The privacy and protection of patient information is a top priority.  South Texas Dermatopathology greatly appreciates the patience and loyalty of its patients as it works to respond to this incident.

SOURCE South Texas Dermatopathology, PLLC


These press releases may also interest you

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

23 avr 2024
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

23 avr 2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: